| Original language | English (US) |
|---|---|
| Pages (from-to) | 1065-1068 |
| Number of pages | 4 |
| Journal | British journal of haematology |
| Volume | 198 |
| Issue number | 6 |
| DOIs | |
| State | Published - Sep 2022 |
Keywords
- myelofibrosis
- prognostic factors
- quality of life
- survival
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: British journal of haematology, Vol. 198, No. 6, 09.2022, p. 1065-1068.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Quality of life independently predicts overall survival in myelofibrosis
T2 - Key insights from the COntrolled MyeloFibrosis Study with ORal Janus kinase inhibitor Treatment (COMFORT)-I study
AU - Kosiorek, Heidi E.
AU - Scherber, Robyn M.
AU - Geyer, Holly L.
AU - Verstovsek, Srdan
AU - Langlais, Blake T.
AU - Mazza, Gina L.
AU - Gotlib, Jason
AU - Gupta, Vikas
AU - Padrnos, Leslie J.
AU - Palmer, Jeanne M.
AU - Fleischman, Angela
AU - Mesa, Ruben A.
AU - Dueck, Amylou C.
N1 - Funding Information: Heidi E. Kosiorek, Holly L. Geyer, Blake T. Langlais, Gina L. Mazza, Jeanne M. Palmer and Leslie J. Padrnos have nothing to disclose. Srdan Verstovsek has research support for conduct of clinical studies and honoraria for participation in advisory boards from Incyte. Srdan Verstovsek receives research support from Incyte, Roche, NS Pharma, Celgene, Gilead, Promedior, CTI BioPharma, Abbvie, Blueprint Medicines Corp., Novartis, Sierra Oncology, PharmaEssentia, Constellation, Italfarma, Protagonist, Kartos and does consulting work with Novartis, BMS and Incyte. Robyn M. Scherber was an employee of Incyte, the sponsor of the COMFORT‐I trial. Angela Fleischman does consulting work with Incyte, BMS, CTI, and PharmaEssentia. Jason Gotlib: Research Funding: Incyte, Novartis, Kartos, Blueprint Medicines, Deciphera, Cogent Biosciences, Abbvie, Celgene, BMS, Protagonist Therapeutics Advisory Boards/Consulting/Honoraria: Incyte, Novartis, Kartos, Blueprint Medicines, Deciphera, Cogent Biosciences, Abbvie, Protagonist Therapeutics, PharmaEssentia. Vikas Gupta received research support from Novartis, Abb Vie, and consulting fees from Novartis, BMS Celgene, Pfizer, Abb Vie, Roche, Incyte and Sierra Oncology. Ruben A. Mesa reports research support from Incyte, Genetech, CTI, Promedior and Abbvie; consultant for Novartis, Sierra Oncology and La Jolla Pharma. RH reports research support from Roche. Amylou C. Dueck receives royalties from commercial licensing of the Myeloproliferative Neoplasm Symptom Assessment Form.
PY - 2022/9
Y1 - 2022/9
KW - myelofibrosis
KW - prognostic factors
KW - quality of life
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85132584276&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132584276&partnerID=8YFLogxK
U2 - 10.1111/bjh.18329
DO - 10.1111/bjh.18329
M3 - Letter
C2 - 35751150
AN - SCOPUS:85132584276
SN - 0007-1048
VL - 198
SP - 1065
EP - 1068
JO - British journal of haematology
JF - British journal of haematology
IS - 6
ER -